Int. J. Mol. Sci., Volume 20, Issue 3 (February-1 2019) – 336 articles
Cover Story (view full-size image): PDAC is the seventh-leading cause of cancer-related deaths, and presents a 5-year survival rate of 8%. These sobering results have spawned the efforts spent on developing novel therapies to improve treatment outcomes. Immunotherapy has become a game changer in cancer care. This remarkable therapeutic approach focuses on taking the breaks off the tumor immune response. Unfortunately, PDAC is considered to be an immunotherapy-resistant disease. Hence, the need for new therapeutic strategies is paramount. Exosomes—extracellular vesicles of endocytic origin—have been acknowledged for their potential as nanocarriers of anti-tumor and immunomodulatory agents. Exosomes are emerging as a powerful tool in immunotherapy, with recent studies showing that exosomes can trigger immune responses against cancer cells. View this paper.
- Issues are regarded as officially published after their release is announced to the table of contents alert mailing list.
- You may sign up for e-mail alerts to receive table of contents of newly released issues.
- PDF is the official format for papers published in both, html and pdf forms. To view the papers in pdf format, click on the "PDF Full-text" link, and use the free Adobe Reader to open them.